SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMPs sharp rally and surge in trading volume are driving attention, with traders debating whether the move reflects accumulation and a lasting breakout or another short-lived pump. Bullish posts point to Flexas European expansion and broader crypto-payments adoption, while skeptics say meaningful usage and sustained demand remain unproven.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

A reported partnership with The Clearing House to support interoperability for tokenized bank deposits is driving attention, with traders tying it to Quants role in financial infrastructure and upcoming Sibos discussion. Bulls also point to QNTs limited supply as fuel for the rally, while skeptics question whether institutional adoption will translate into lasting token demand.

VeChain is a public Layer-1 blockchain designed for real-world applications. Founded in 2015, its VeChainThor network supports enterprise and consumer use cases involving supply chains, product provenance, sustainability, digital product passports, tokenized incentives and verifiable data.  VeChainThor combines EVM-compatible smart contracts with a dual-token model, native fee delegation and multi-clause transactions. VET is the network’s native asset and staking collateral, while VTHO is used to pay transaction fees and execute smart contracts.  VeChain’s ecosystem includes VeBetter, an app platform that rewards verified positive actions; StarGate, its NFT-based staking platform; VeWorld, its self-custody wallet; and VeWorld.ai, its AI-agent platform. In its April 2026 roadmap, VeChain reported that VeBetter had reached 5.3 million users, more than 50 live applications and over 50 million verified actions.  VeChain has also worked with organizations including Walmart China, DNV, PwC, Boston Consulting Group and UFC across enterprise, sustainability and consumer initiatives.

Vechain

VET is drawing attention for a rebound and breakout attempt after a prolonged decline, with traders focused on a move back above the penny level. Bulls point to VeChain network upgrades and potential adoption, while skeptics question whether the recovery can hold given the tokens extended underperformance.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

Claims of a BONK DAO exploit involving stolen tokens, alongside concern about an Upbit delisting, dominate the discussion. Traders debate whether the resulting weakness is a dip-buying opportunity or a sign of deeper security and trust problems.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FETs rebound is drawing attention amid renewed interest in AI-focused crypto and autonomous-agent projects, with traders pointing to Fetch/ASI product activity and its planned agent infrastructure as reasons for optimism. The move has prompted breakout and accumulation talk, but skeptics question whether the rally can hold, citing Bitcoins influence, resistance levels, and uncertainty about real-world adoption.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is drawing attention after Panasonic Advanced Technology and Jasmy/JANCTION presented a working Smart Render product using distributed GPUs, with commercial use cases in view. Traders are treating the development as evidence of real utility, while skeptics question how much it will drive demand for the token, since direct JASMY use in payments has not been confirmed.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Attention centers on the anticipated unified Aero multi-chain rollout, which traders say could expand Aerodrome beyond Base to Ethereum and additional networks, broadening its liquidity reach. Many are bullish on the recent momentum and expected expansion, while others warn of a selloff around the launch and question whether the gains can hold.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is drawing attention after reports that U.S. export controls led Anthropic to restrict access to its advanced AI models, prompting traders to favor decentralized AI networks. The community sees TAO as a potential open alternative to centralized AI, though some remain cautious about whether that narrative will translate into sustained adoption.

XYO is the cryptographic proof layer for the real world, collecting, validating, and delivering physical-world data to AI, robotics, Web3, and enterprise systems. XYO, the original Decentralized Physical Infrastructure Network (DePIN), has been operating since 2018 and now has more than 10 million nodes worldwide.   At the core of XYO is XYO Layer One, a scalable data blockchain built to support high-volume data industries such as AI, robotics, location intelligence, and real-world asset (RWA) systems. Designed for high throughput and low transaction costs, it gives these data-intensive applications the capacity to process and validate information across massive datasets. XYO Layer One anchors XYO's Proof of Location and Proof of Origin technologies, establishing a verified origin, precise timing, and trusted source behind every piece of data. This verified data directly feeds the XYO AI SDK, a product built by XYO to provide accessibility for developers to build AI-powered applications, autonomous agents, robotics integrations and more using real-world data.  XYO employs a unique dual-token model:  XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases.  The dual-token economics are strategically designed to increase scarcity and promote sustainable growth.   The XYO token has been available on major exchanges since 2018. Major exchanges include Coinbase and Revolut. The XL1 token is now also available.

XYO Network

XYOs recurring short-lived price pops and failure to hold gains dominate discussion, with skeptics calling the moves pump-and-dump activity and pointing to weak volume. Bullish traders are positioning for a breakout and speculating about future announcements or AI/DePIN partnerships, but no specific new catalyst is clearly established.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

Persistent selling and bearish chart signalsincluding a break of rising support and renewed bear-flag concernsare dominating discussion, with traders noting that positive WeRide developments have not lifted the shares. The community is divided between those expecting further downside and long-term bulls who see improving autonomous-driving prospects as a potential counterweight.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Johnson & Johnson is repeatedly named by traders as a possible buyer of Sellas Life Sciences, with speculation linked to Sellass pending REGAL trial results and J&Js oncology ambitions; no deal is confirmed. The conversation also includes bullish reactions to JNJs recent strength, alongside some technical concerns.

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAbbVie continues to diversify its portfolio into neuroscience and aesthetics to offset the loss of patent exclusivity for older drugs...

Johnson & Johnson Clinical Trials Show Progress Across Key Therapies

Johnson & Johnson shares key clinical trial results for Tremfya in psoriatic arthritis and five-year Carvykti data in multiple myeloma.read more...

Johnson & Johnson announces TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson announces TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study Johnson & Johnson announces TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show...

Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in...

Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

New model-based analysis further supports the potential of TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

New model-based analysis further supports the potential of TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma New model-based analysis further supports the potential of...

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal

Key PointsJohnson & Johnson announced plans to spin off its orthopedics business in late 2025...

CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study

CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 studyPR NewswireTITUSVILLE, N.J., Sept. 21, 2026CAPLYTA significantly reduced the signs and...

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?

AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

LEGN’s New CEO From Novartis Paves Way For Buyout Speculation 

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

JNJ Johnson & Johnson